The segment is impelled by the broad use and proven efficacy of various injectable formulations, including dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy), and liraglutide (Victoza, Saxenda) in managing type 2 diabetes and obesity
Total Revenue: $26.74B Founded Year: 1885 Total Employees: 54,300 Headquarters: Ingelheim, Germany Market Cap: N/A Stock Exchange: N/A Boehringer Ingelheim (BI) is a research-driven biopharma company operating across human pharmaceuticals and animal health, with a strong focus on cardiometabolic diseases, respiratory conditions, oncology, and immunology anchored by a pipeline-led innovation strategy
Contact us today: Email: [email protected] Website: WhatsApp: +919970006978 #PharmaceuticalIndustry #GlobalHealthcare #DrugInnovation #Biotechnology #Oncology #Immunotherapy #PrecisionMedicine #PharmaExports #HealthcareInnovation #LifeSciences To view or add a comment, sign in 5,089 followers Explore related topics Trends in Glp-1 Treatment Options Trends Shaping Drug Development How Glp-1 Drugs Impact Economic Trends Trends in Weight Loss Drug Accessibility Trends Shaping the Future of Therapeutics Key Trends in Biopharma Services Trends Shaping Pharmacy and Healthcare Trends in Obesity Treatment Options Innovations Transforming Prescription Drug Care Impact of Glp-1 Medications on Health
Similar to quadrivalent HPV vaccine (4vHPV), 9vHPV contains HPV 6, 11, 16, and 18 VLPs
However, it is only one part
Stay ahead of the curve with valuable resources and strategic recommendations
